Table 2.

Genotype-Specific Risks of Endometrial Cancer for Selected Single Nucleotide Polymorphisms^a, Shanghai Endometrial Cancer Study, Shanghai, China, 1997–2003

Gene	Single Nucleotide Polymorphism	Minor/Major Alleles	Region	Minor Allele Frequency	PHWE	Endometrial Cancer Risk
						Heterozygosity (AB)		Minor-Allele Homozygosity (BB)		Additive Ptrend	Adjusted P Valueb
						ORc	95% CI	ORc	95% CI
CCNB1	rs2069433	C/T	Intron	7.28	1.00	0.79	0.60, 1.02	0.35	0.08, 1.46	0.030	0.081
CDK6	rs2282978	C/T	Intron	11.30	1.00	0.79	0.63, 1.00	0.75	0.34, 1.68	0.040	0.413
CDK6	rs2282979	C/T	Intron	10.81	0.89	0.80	0.64, 1.01	0.67	0.28, 1.57	0.042	0.424
CDKN1B	rs11055027	C/G	Promoter	18.24	0.73	1.21	0.99, 1.48	1.89	1.12, 3.19	0.006	0.068
CDKN1B	rs3759216	A/G	Promoter	43.66	0.38	0.76	0.62, 0.93	0.73	0.56, 0.94	0.008	0.084
CDKN1B	rs34330	T/C	5′ untranslated	49.75	0.18	1.33	1.06, 1.66	1.51	1.16, 1.94	0.002	0.025
CDKN1B	rs34322	C/T	3′ flanking	48.35	0.49	0.84	0.67, 1.04	0.73	0.57, 0.94	0.015	0.142

Abbreviations: CI, confidence interval; HWE, Hardy-Weinberg equilibrium; OR, odds ratio.

^aSingle nucleotide polymorphisms were selected on the basis of P_trend < 0.05 and P_HWE > 0.05.

^bAdjusted P values are presented because of multiple correlated tests (26).

^cAdjusted for age at interview, body mass index, menopausal status, education, income, alcohol consumption, age at menarche, number of livebirths, and occupation. Major-allele homozygosity (AA) was the reference category.